The TNT protocol: A phase II study using talimogene laherparepvec (TVEC), nivolumab (N) and trabectedin (T) as first, second/third line therapy for advanced sarcoma, including desmoid tumor and chordoma.

Sant P. Chawla,Victoria S Chua,Katherine K. Kim,Paul Stendahl Dy,Micaela Kristina Paz,Nicole Angel,Kelly Wang,Ania Moradkhani,Doris Quon,Steven G. Wong,Omid Jafari,Erlinda M. Gordon

The TNT protocol: A phase II study using talimogene laherparepvec (TVEC), nivolumab (N) and trabectedin (T) as first, second/third line therapy for advanced sarcoma, including desmoid tumor and chordoma.

2020

Sant P. Chawla
Victoria S Chua
Katherine K. Kim
Paul Stendahl Dy
Micaela Kristina Paz
Nicole Angel
Kelly Wang
Ania Moradkhani
Doris Quon
Steven G. Wong
Omid Jafari
Erlinda M. Gordon

TPS11572Background: Talimogene laherparepvec (TVEC), an oncolytic HSV expressing huGMCSF, may be synergistic with trabectedin (T) and nivolumab (N) in treating advanced sarcoma. Objectives: (1) To ...

Keywords:

Oncology
Sarcoma
Talimogene laherparepvec
TNT protocol
Internal medicine
Trabectedin
Pathology
Phases of clinical research
Nivolumab
Chordoma
Third-line therapy
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations